ST. PAUL, Minn., Oct. 8 Brennen Medical, LLC a leader inbiomaterial technology announces the nationwide availability of itsXenMatriX(R) product for soft tissue reconstruction. Brennen Medical receivedclearance to market XenMatriX(R), via the FDA 510k process, into the surgicalhernia market. Surgeons are successfully implanting XenMatriX in ventralhernia/abdominal wall procedures, including complex repairs.
XenMatriX(R) is designed for use in the treatment of abdominal wall(hernia) repair where the connective tissue has ruptured. With the agingpopulation and the obesity epidemic, over 30% of people over the age of 55will seek treatment for soft tissue reinforcement. XenMatriX offers asuccessful alternative to synthetic materials for this population in need ofsurgical intervention.
XenMatriX(R) employs a patented technology that maintains an acellular,structurally intact, non-crosslinked porcine dermal matrix for enhancedbiocompatibility in host tissue. This non-crosslinked dermal matrix supportstissue revascularization, remodeling and regeneration for abdominal wall andhernia repairs. The compatibility and strength of this material minimizeshernia recurrence and pain, which also minimizes expense for both the patientand the healthcare environment.
Phillip Lawin, President of Brennen Medical said, "We are extremelypleased with the outcomes of XenMatriX. Unlike traditional mesh products,XenMatriX(R) can be used successfully in contaminated or potentiallycontaminated and complex fields. This provides patients and surgeons a trulysafe and effective alternative for abdominal wall hernia repair."
About Brennen Medical
Brennen Medical is a world leader providing biologic porcine xenograft foruse in plastic reconstructive, general surgical, burn, trauma, wound,urogynecological and orthopedic soft tissue repair procedures. Demonstratedto be effective, surgeons have used Brennen's proprietary porcine technologiesfor over 40 years. Mediskin(TM)and EZ Derm(TM), XenMatriX(R), andDermMatrix(R) provide the basis for innovation and quality to guide theCompany's initiatives for a growing biosurgical market. Based in St. Paul, MNand privately held, the products are sold through a direct sales force andthrough partnerships with major medical device companies. In addition toporcine, Brennen also markets a line of products containing beta glucan, anatural complex carbohydrate providing improved wound healing and host tissueregeneration. The company maintains a web site at http://www.brennenmed.com.
SOURCE Brennen Medical, LLC